摘要
目的探讨卡马西平、托吡酯与丙戊酸钠治疗脑炎继发癫痫的临床疗效。方法选取本院2006年3月至2011年4月收治的脑炎继发癫痫患者93例,随机分为三组,采用卡马西平(300mg/d)治疗患者31例为观察Ⅰ组,采用托吡酯(起始剂量为25mg/d,每周增加25mg/d,目标剂量为100mg/d)治疗患者31例为观察Ⅱ组,采用丙戊酸钠(500mg/d)治疗患者31例为观察Ⅲ组,疗程均为1年,比较三组患者治疗后的临床疗效及不良反应情况。结果治疗总有效率由高到低分别为观察Ⅲ组(77.4%)、观察Ⅱ组(74.2%)、观察Ⅰ组(67.7%),差异均无统计学意义(P>0.05)。不良反应发生率由高到低分别为观察Ⅰ组(38.7%)、观察Ⅲ组(22.6%)、观察Ⅱ组(9.7%),差异均有统计学意义(P<0.05)。结论卡马西平、托吡酯与丙戊酸钠治疗脑炎继发癫痫的临床疗效相当,托吡酯不良反应发生率最低更适合于临床应用。
Objective Carbamazepine, topiramate and sodium valproate treatment of encephalitis, the clinical efficacy of secondary epilepsy. Methods A hospital from March 2006 to April 2011 93 cases of encephalitis admitted patients with epilepsy secondary, were randomly divided into three groups, patients treated with carbamazepine (300mg/d) , 31 cases observed in group I topiramate (starting dose 25rag/d, weekly 25mg/d target dose of 100mg/d) treatment of 31 patients, the use of sodium valproate (500mg/d) to observe the group I:I patients treated with 31 cases observed Ⅲ group, the course of one year, the clinical efficacy and adverse effects compare three groups of patients after treatment. Results The overall efficiency from high to low were observed in group Ⅲ (77.4%) , observed in group Ⅱ (74.2%) observed in group I (67.7%) showed no significant difference (P〉 0.05) . The incidence of adverse reactions from high to low were observed in group I (38.7%) , observation of the III group (22.6%) , and observe the II group (9.7%) , the differences were statistically significant (P〈0.05) . Conclusion The clinical efficacy of carbamazepine, topiramate and sodium valproate in the treatment of epilepsy encephalitis secondary incidence of adverse events of topiramate minimum is more suitable for clinical application.
出处
《中国医药指南》
2012年第20期415-416,共2页
Guide of China Medicine
关键词
卡马西平
托吡酯
丙戊酸钠
脑炎继发癫痫
Carbamazepine
Topiramate
Sodium valproate
Encephalitis secondary to epilepsy